Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Infectious Disease Diagnostic Market By Type (Products [Instruments, Reagents And Kits] And Services), By Technology (Genetic Material Based, Immunoassays, Microbial Cultures, And Others) By Application (Viral Diseases, Bacterial Diseases, And Others) By End-User (Hosptials, Diagnostic Labs, And Others) by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to surge in prevalence of infectious diseases and growing concern regarding the incidences of pandemic and epidemics.

Infectious Disease Diagnostics Market Dynamics:

Among the noteworthy drivers of the infectious disease diagnostics market, the rising prevalence of infectious diseases turns out to be the major factor for accelerating the infectious disease diagnostics market. For instance, according to the World Health Organization (WHO) 2022, globally there were around 37.7 million people suffering from human immunodeficiency virus (HIV) in year 2020. One of the diagnostic test for HIV is Nucleic Acid Test (NAT), where the blood is usually drawn from the vein and tested for the presence of virus. The test also measures the viral load in a blood sample.

Further, rising incidences of epidemics and pandemics across the world is going to boost the market growth for infectious disease diagnostics. For example, the unprecedented outbreak of the COVID-19 pandemic became one of the most dangerous challenges the world has ever faced. It resulted in a humanitarian crisis with severe health and socio-economic consequences across the globe. According to WHO 2022, worldwide there have been 4,249,488 confirmed cases of COVID-19 at the end of 2020 and around 10,124,070 cases at the end of 2021. The diagnostic techniques such as Quantitative or Real-time reverse transcription polymerase chain reaction (qRT-PCR or rRT-PCR), immunoassays, and others were employed in the detection of SARS-CoV-2 virus which is the causative agent for COVID- 19.

Another key factor responsible for the growth of the infectious disease diagnostics market is the increasing prevalence of malaria. For instance, as per the latest data provided by the World Health Organization 2022, globally around 241 million people had suffered from malaria in 2020. The microscopic examination of patients' blood specimen using Giemsa stain is considered as the “gold standard” method for confirmation of malaria. Rapid diagnostic tests are alternative and quick method for the diagnosis of malaria.

However, the risk of blood sample contamination during transport and storage, the lack of skilled phlebotomists and high cost of diagnostic tests may act as restraining factors to the infectious disease diagnostics market growth.

The infectious disease diagnostics market reported a short period of restraint in the market growth during the initial phases of the pandemic due to the implementation of lockdown as necessary measures to prevent the spread of COVID-19 infection leading to the suspension of routine diagnostic checkups. Also, during the initial phases owing to the lockdown, the manufacturing and supply of diagnostic kits, and others were affected leading to further decline in the market. But later owing to the tremendous increase in the COVID-19 cases the demand for COVID- 19 testing along with test for other respiratory diseases increased leading to slight improvement in the infectious disease diagnostics market. Moreover, with the resumption of activities including diagnostic tests for other infectious diseases, and others across industries including the healthcare sector, it has been uplifting for the infectious disease diagnostics market during the forecast period from 2022-2027.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments, Reagents and Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others) Application (Viral, Bacterial, and Others) End-User (Hospitals, Diagnostic Labs, and Others) Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Based on the technology segment of the infectious disease diagnostics market, the immunoassays category is projected to register a significant growth in the revenue of the infectious disease diagnosis market during the forecast period (2022-2027).

This can be ascribed to the superior diagnostic features associated with the immunoassays over other diagnostic tests. Immunoassays are based on antigen-antibody reactions and therefore they are highly sensitive and specific for the detection of infectious diseases.

Immunoassays are more readily available, accessible, easy to use, and have rapid turnaround time when compared to other methods of disease diagnosis. Also, the immunoassays are less costly than high tech instruments which are currently utilized for infectious disease diagnosis.

Although immunoassays are used as confirmatory tests along with other tests for infectious disease diagnosis but in certain diseases such as Lyme disease, syphilis, and others, they are primary means for disease detection.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In November 2020, Hologic, Inc., received U.S. Food and Drug Administration (FDA) approval for its Aptima® HIV-1 Quant Dx assay which is the first dual-claim assay for both diagnosis and viral load monitoring. Therefore, considering the advantages associated with the immunoassays and their growing popularity among the end-users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global infectious disease diagnostics market during the forecast period.

North America is expected to dominate the overall Infectious Disease Diagnostics Market:

Among all the regions, North America is expected to lead in revenue generation of global infectious disease diagnostics market. This can be ascribed to the presence of large patient pool associated with infectious diseases including Sexually transmitted diseases (STSs), TB, and others, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region. According to Centers for Disease Control and Prevention 2022, it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019.

Another factor contributing in the growth of infectious disease diagnostics is the increasing cases of tuberculosis. For instance, as per the Centers for Disease Control and Prevention 2022, there were around 7,860 cases of TB reported in 2021 in the United States. As per the same source, currently around 13 million people are living with latent TB infection in the US. The Mantoux tuberculin skin test (TST) is widely used for the screening of tuberculosis.

Moreover, the presence of key market players including BD, Abbott, and Thermo Fisher Scientific Inc. among others along with continuous regulatory approvals are likely to increase the demand for infectious disease diagnostics.

For instance, in July 2022 DiaSorin received the US FDA 510(k) clearance for LIAISON® MeMed BV® Test which is intended for differentiating between the viral and bacterial infections.

Therefore, along with the presence of large patient pool in the country, the increasing focus of key manufacturers on launching the new products in the market is expected to bolster the growth of the infectious disease diagnostics market in the United States during the forecast period.

Infectious Disease Diagnostics Market Key Players:

Some of the key market players operating in the Infectious Disease Diagnostics Market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in Infectious Disease Diagnostics Market:

• In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
• In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.
• In March 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

Key Takeaways from the Infectious Disease Diagnostics Market Report Study

• Market size analysis for current infectious disease diagnostics market size (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the infectious disease diagnostics market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
• Key companies dominating the global infectious disease diagnostics market.
• Various opportunities available for the other competitor in the infectious disease diagnostics market space.
• What are the top performing segments in 2021? How these segments will perform in 2027.
• Which is the top-performing regions and countries in the current infectious disease diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target Audience who can be benefited from this Infectious Disease Diagnostics Market Report Study

• Infectious diseases diagnostic products providers
• Research organizations and consulting companies
• Infectious diseases diagnostic -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in infectious diseases diagnostic
• Various end users who want to know more about the infectious disease diagnostics Market and latest technological developments in the infectious disease diagnostics market.

Frequently Asked Questions for Infectious Disease Diagnostics Market:

1. What are infectious disease diagnostics?

Infectious disease diagnostics comprises of diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

2. What is the market for the global infectious disease diagnostic?

The global infectious disease diagnostics market was valued at USD 38.52 billion in 2021 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022-2027) to reach USD 48.10 billion by 2027.

3. What are the drivers for the global infectious disease diagnostics market?

The infectious disease diagnostics market is slated to witness prosperity owing to factors such as increase in the prevalence of infectious diseases such as COVID-19, and HIV among others, technological advancements such as use of AI, rising incidences of epidemics and pandemics, and the growing focus on improving the safety and usability of infectious disease diagnostics for end users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2022-2027).

4. Who are the key players operating in the global infectious disease diagnostics market?

Some of the key market players operating in the infectious disease diagnostics market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

5. Which region has the highest share in the infectious disease diagnostics market?

North America is expected to dominate the overall infectious disease diagnostics market during the forecast period, 2022 to 2027. This can be ascribed to the presence of large patient pool associated with multiple infectious diseases such as STS, Tuberculosis, HPV, and others, high tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.